Gene · 4921
Papers2,653
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,261 to 1,280 of 2,653
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. | Food Chem Toxicol | 2020 | 32234424 | PubTator, text mining | PubMed |
| Comparison of Fresh Frozen Tissue With Formalin-Fixed Paraffin-Embedded Tissue for Mutation Analysis Using a Multi-Gene Panel in Patients With Colorectal Cancer. | Front Oncol | 2020 | 32232001 | PubTator, text mining | PubMed |
| Identification of novel regulators of STAT3 activity. | PLoS One | 2020 | 32231398 | PubTator, text mining | PubMed |
| In Situ Expansion, Differentiation, and Electromechanical Coupling of Human Cardiac Muscle in a 3D Bioprinted, Chambered Organoid. | Circ Res | 2020 | 32228120 | PubTator, text mining | PubMed |
| Integrated bioinformatics analysis of aberrantly-methylated differentially-expressed genes and pathways in age-related macular degeneration. | BMC Ophthalmol | 2020 | 32209064 | PubTator, text mining | PubMed |
| Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma. | Lung Cancer | 2020 | 32208298 | PubTator, text mining | PubMed |
| Tumor mutation burden derived from small next generation sequencing targeted gene panel as an initial screening method. | Transl Lung Cancer Res | 2020 | 32206555 | PubTator, text mining | PubMed |
| Over expression of CDK4 and MDM2 in a patient with recurrent ALK-negative mediastinal inflammatory myofibroblastic tumor: A case report. | Medicine (Baltimore) | 2020 | 32195970 | PubTator, text mining | PubMed |
| A Comparative Analysis of Tumors and Plasma Circulating Tumor DNA in 145 Advanced Cancer Patients Annotated by 3 Core Cellular Processes. | Cancers (Basel) | 2020 | 32188081 | PubTator, text mining | PubMed |
| Design and Optimization of 3'-(Imidazo[1,2-a]pyrazin-3-yl)-[1,1'-biphenyl]-3-carboxamides as Selective DDR1 Inhibitors. | ACS Med Chem Lett | 2020 | 32184973 | PubTator, text mining | PubMed |
| Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors. | J Clin Oncol | 2020 | 32182156 | PubTator, text mining | PubMed |
| A Pilot Study of Baseline Spatial Genomic Heterogeneity in Primary Gastric Cancers Using Multi-Region Endoscopic Sampling. | Front Oncol | 2020 | 32158697 | PubTator, text mining | PubMed |
| Comprehensive RNA Sequencing in Adenoma-Cancer Transition Identified Predictive Biomarkers and Therapeutic Targets of Human CRC. | Mol Ther Nucleic Acids | 2020 | 32145677 | PubTator, text mining | PubMed |
| Label-free quantitative identification of abnormally ubiquitinated proteins as useful biomarkers for human lung squamous cell carcinomas. | EPMA J | 2020 | 32140187 | PubTator, text mining | PubMed |
| Expression Profiling of Driver Genes in Female Never-smokers With Non-adenocarcinoma Non-small-cell Lung Cancer in China. | Clin Lung Cancer | 2020 | 32139332 | PubTator, text mining | PubMed |
| Major response to temozolomide as first-line treatment for newly-diagnosed DDR2-mutated glioblastoma: A case report. | Rev Neurol (Paris) | 2020 | 32139182 | PubTator, text mining | PubMed |
| Development of genetic quality tests for good manufacturing practice-compliant induced pluripotent stem cells and their derivatives. | Sci Rep | 2020 | 32127560 | PubTator, text mining | PubMed |
| Validation and implementation of a modular targeted capture assay for the detection of clinically significant molecular oncology alterations. | Pract Lab Med | 2020 | 32123717 | PubTator, text mining | PubMed |
| Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer. | Cancers (Basel) | 2020 | 32120793 | PubTator, text mining | PubMed |
| Collagen Kinase Receptors as Potential Therapeutic Targets in Metastatic Colon Cancer. | Front Oncol | 2020 | 32117772 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4921/papers?page=64